반려동물용 백신 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Companion Animal Vaccines Market was valued at USD 3.5 billion in 2024 and is estimated to grow at a CAGR of 6.5% to reach USD 6.4 billion by 2034. This promising growth trajectory stems from a combination of factors such as increasing pet ownership, rising awareness around animal health, and the expanding trend of pet humanization. As households across the globe continue to adopt pets at a steady pace, the need for preventive healthcare solutions like vaccinations is growing rapidly. Pet owners are prioritizing the overall health and well-being of their companion animals, often equating their care to that of human family members. This shift in attitude is fueling investments in routine veterinary care, creating a surge in demand for vaccines that protect pets from infectious diseases. Moreover, global animal health organizations are promoting early vaccination programs, reinforcing the importance of immunization in reducing the prevalence of zoonotic diseases and improving public health outcomes. The growing emphasis on early-stage disease prevention, supported by rising disposable incomes and advancements in veterinary services, is setting the stage for sustained market expansion through the next decade.

The companion animal vaccines market is segmented by vaccine type, including attenuated live vaccines, conjugate vaccines, inactivated vaccines, DNA vaccines, recombinant vaccines, and others. Among these, the attenuated live vaccine segment was valued at USD 1.5 billion in 2024. These vaccines are favored for their ability to trigger a strong immune response and deliver long-lasting immunity with fewer booster doses. They use weakened forms of pathogens to stimulate immunity, offering effective protection against a variety of infectious conditions. Pet owners and veterinarians continue to choose this vaccine type for its cost-efficiency, reliability, and ability to minimize disease outbreaks in pets.

In terms of animal type, the market is categorized into canines, felines, equines, and avians. The canine segment accounted for 53.4% of the overall market share in 2024, supported by the increasing global dog population and rising awareness of canine health. Countries with high dog ownership rates are witnessing growing demand for targeted vaccine products. Manufacturers are continuously innovating and expanding their vaccine portfolios tailored specifically to dogs, supporting the dominance of the canine segment in the market.

The U.S. Companion Animal Vaccines Market reached USD 1.23 billion in 2023. High pet ownership, coupled with an advanced veterinary healthcare infrastructure, is driving consistent vaccine demand. The pet humanization trend further supports spending on routine checkups and immunizations. With key pharmaceutical companies like Zoetis, Merck Animal Health, Elanco Animal Health, and others leading innovation, the U.S. remains a pivotal market in this space.

Key players in the global market are focused on enhancing their vaccine offerings through R&D, partnerships with veterinary clinics, and regional expansions. Companies such as Vetoquinol, Virbac, Boehringer Ingelheim International, Bioveta, Sinovac, Biogenesis Bago, Brilliant Bio Pharma, HIPRA, and others are developing effective, affordable solutions to meet the evolving needs of global pet owners.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing pet ownership and spending
    • 3.2.1.2 Growing awareness about companion animal vaccination
    • 3.2.1.3 Growing number of insured pets
    • 3.2.1.4 Rising prevalence of zoonotic diseases
    • 3.2.1.5 Increasing government initiatives for companion animal vaccination
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of vaccine development
    • 3.2.2.2 Stringent regulatory scenario for vaccine development
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 List of core and non core vaccines by animal type
  • 3.5.1 Canine
  • 3.5.2 Feline
  • 3.5.3 Equine
  • 3.5.4 Avian
• 3.6 Regulatory landscape
• 3.7 Porter’s analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Attenuated live vaccine
• 5.3 Conjugate vaccine
• 5.4 Inactivated vaccine
• 5.5 DNA vaccine
• 5.6 Recombinant vaccine
• 5.7 Other vaccine types

Chapter 6 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Canine
• 6.3 Feline
• 6.4 Equine
• 6.5 Avian

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Parenteral
• 7.3 Oral
• 7.4 Nasal

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Boehringer Ingelheim International
• 10.2 Brilliant Bio Pharma
• 10.3 Bioveta
• 10.4 Biogenesis Bago
• 10.5 Ceva Sante Animale
• 10.6 Durvet
• 10.7 Elanco Animal Health
• 10.8 HIPRA
• 10.9 Indian Immunologicals
• 10.10 Merck Animal Health
• 10.11 Sinovac
• 10.12 Vetoquinol
• 10.13 Virbac
• 10.14 Zoetis